Otis Clapp & Son, Inc. v. Filmore Vitamin Company D/B/A Medique ProductsOtis Clapp & Son, Inc. v. Filmore Vitamin Company D/B/A Medique Products
The plaintiff appeals not only the amount it recovered in an unfair trade competition action but also the denial of motions to supplement its complaint and to compel discovery. We affirm.
I.
Both the plaintiff, Otis Clapp & Son, Inc. (“Otis Clapp”) and the defendant, Medique Products (“Medique”), a division of the Filmore Vitamin Company, sell non-prescription pharmaceuticals in the institutional medical market. Both companies sell their pharmaceutical supplies through distributors to the end-purchasers who, typically are nurses employed in plant or office clinics. Medique entered the market in 1975 or 1976 and developed a line of pharmaceuticals that competed against many of Otis Clapp’s products. At that time, Otis Clapp was an established and growing business.
Otis Clapp complained of five unfair trade practices by Medique: (1) infringement of several of its trademarks; (2) false, misleading, and deceptive comparative advertising; (3) false statements about the quality and effectiveness of Otis Clapp products and their ingredients; (4) false representations that certain Otis Clapp products did not conform to Food and Drug Administration Guidеlines; and (5) the hiring of James Rose, a former Otis Clapp employee, in order that they might obtain confidential information from him. 1 Specifically, Otis Clapp asserted that FEMAIDS, Medique’s menstrual relief medication, infringed Otis Clapp’s trademark for FEM-CAPS, also a menstrual relief medication. Furthermore, Otis Clapp objected to Medique’s use of the name DISPENSER-PAK for its individual dose dispensing packaging as an infringement of Otis Clapp’s DIS-PENS-A-KIT trademark, used by Otis Clapp to describe similar packaging. The comparative advertising and false statement claims were based on a 1977 Medique brochure, which was used both as a sales promotion device and to interest new distributors in handling the Medique line. In addition, the literature was also given to existing Medique distributors to be disseminated to final purchasers.
Otis Clapp filed its complaint in 1978 alleging claims under Section 35 of the Lanham Act (“Act”),
On October 22, 1982, the defendant admitted liability under the Lanham Act and state law claims without conceding damages. The defendant’s counsel informed the court that his client was without funds, could not afford to pay attorney’s fees, and could not afford to respond to the plaintiff’s discovery program. According to the representations made to the district court, the defendant admitted liability solely because it was financially unable to litigate the issue. Attempting to avoid both a damages hearing and supplemental proceedings under
During monthly status hearings held from November 22, 1982 through February 15, 1983, the parties presented several of
On February 16, 1983, the district court scheduled a trial on the damages issue for April 14, 1983. On February 25, 1983, the plaintiff filed a request for production of documents. On March 11, 1983, the plaintiff filed a “motion for clarification of defendant’s identities, substitution of defendants, and to file an amendment to the complaint.” According to the record, the plaintiff sought the documents from the defendant in order that they might establish that Medique’s unfair trade practices were both continuing and intentional. Furthermore, the plaintiff sought documents pertaining to the defendant’s sales and costs. In its motion to amend the complaint, the plaintiff requested the court to grant them leave to add comparison literature issued by the defendant in addition to the 1977 brochure attached to the complaint. Secondly, the plaintiff wished to add Irving Udell and the new Filmore Vitamin Company as defendants. The district court denied the motions noting, “the plaintiff a year ago or more recognized that — well, in fact, longer ago than that — recognized that it might have a subsequent and different claim against the defendant for conduct following the filing of the complaint.” Thus, those portions of the motions directed towards conduct subsequent to the filing of the complaint were denied because “[tjhere comes a time when a five-year-old lawsuit needs to get put to bed.” Those portions of the motions concerning the identity of the defendants, and the attempt to add defendants, were denied because their grant would of necessity require new and lengthy discovery and thus would prolong the litigation. Specifically, the distriсt court held that the diversion of assets question would be more appropriately resolved in a supplemental proceeding.
At the trial on damages, the plaintiff presented evidence on consumer reactions to Medique’s advertising. Even though the consumers were concerned, they were not influenced enough to cease and desist from using Otis Clapp products. The plaintiff also introduced financial evidence as to Medique’s sales, the cost of a curative advertising campaign, and proof of attorney’s
Noting that the plaintiff failed to prove lost sales, the district court analyzed the plaintiff’s proof of unrealized growth and concluded that the plaintiff’s evidence failed to establish that the failure to grow as projected was caused by the defendant’s actions. The district court did, however, allow the plaintiff to recover the full cost of its curative advertising campaign. As to attorney’s fees, the district court commented that it “is persuaded that plaintiff has, throughout this litigation, overreacted to the impact of defendant’s conduct and that an action which should have largely sought injunctive relief became, over time, more complex and more intensively litigated than it should have been.” Particularly, the district court noted that, “after the concession of liability, the costs to both parties were substantially and unnecessarily increased by plaintiff’s litigation strategy.” On the other hand, the district court was also “persuaded that the ‘targeting’ of plaintiff by defendant in its literature was in cavalier disregard of the objective truth.” Furthermore, the “[djefendant’s litigation strategy, until its concession of liability, did not facilitate the resolution of the dispute.” The district court concluded that the plaintiff was entitled to $20,000 in attorney’s fees. Turning to the question of whether the defendant had to disgorge its FEMAIDS profits, the district court found that Medique had suffered losses from 1978 through 1981. Rather than find that the plaintiff could not recover for lost profits, the court awarded the defendant 15 percent of the amount received from the sale of FEMAIDS from 1978 through 1982. 5 The plaintiff appeals the denial of discovery, the denial of its motion to supplemеnt the complaint and the amount of its recovery.
II.
A. The Procedural Rulings.
Our initial inquiry is whether the district court erred in denying the motion to supplement the complaint by adding post-complaint literature and additional parties. Otis Clapp argues that the addition of the post-complaint literature was necessary “to put into issue the repetition of falsehoods and misleading statements over an extended period.” Relying upon
“The most significant feature ofRule 25(c) is that it does not require that anything be done after an interest has been transferred. The action may be continued by or against the original party, and the judgment will be binding on his successor in interest even though he is not named. An order of joinder is merely a discretionary determination by the trial court that the transferee’s presence would facilitate the conduct of the litigation.”
7A Wright and Miller, Federal Practice and Procedure § 1958, at 664-65 (footnotes omitted);
see e.g., Kaplan v. Joseph,
Otis Clapp argues that its motion to compel the production of documents was necessary “to permit a more complete resolution of this matter through the damages hearing, and to better ascertain the extent of Medique’s activities.” The district court
B. The Relief Granted.
[8-10] “[Sjubject to the principles of equity,” the Lanham Act allows the successful litigant to recover: “(1) defendant’s profits; (2) any damages sustained by the plaintiff; and (3) the costs of the action.”
To force the defendant to disgorge the profits obtained because of the infringement, the Act requires, “the plaintiff ... to prove defendant’s sales only; defendant must prove all elements of cost or deduction claimed” in determining the profit derived from the sale. The defendant may show that his infringement was not profitable.
Mishawaka Rubber & Woolen Mfg. Co. v. S.S. Kresge Co.,
When determining damages in an unfair trade practices case, the courts distinguish between the amount of proof needed to show “that some damages were the cеrtain result of the wrong” and the amount of proof needed to ascertain the exact amount of damage.
Bigelow v. RKO Radio Pictures, Inc.,
The plaintiff asserted three claims for damages: (1) unrealized growth potential; 8 (2) attorney’s fees; and (3) the expense of a curative advertising campaign. The plaintiff received full reimbursement for its curative advertising campaign and challenges only the court’s rulings on the other two claims for damages. Initially, we turn to the claim that the defendant’s activities caused the plaintiff to fail to reach its projected or anticipated growth. In essence, the plaintiff presented a mathematical projection to demonstrate to the court what its growth would have been if the defendant had not engaged in unfair trade practices. To present an accurate estimate, the plaintiff adjusted its figures to remove the effects of inflation, price increases, and the impact of the recession on the number of hours worked by industrial workers, the ultimate consumers of Otis Clapp’s products. Assuming that Otis Clapp would have grown at the rate it experienced in the past, the plaintiff established what its sales would or should have been had it actually grown at that rate. By comparing its estimated growth with its actual growth (using figures adjusted to remove thе effects of inflation, price increases, and the recession), the plaintiff determined both the decrease in growth for the company as a whole and the decrease in growth of the products mentioned in Medique’s literature. Finally, the plaintiff used the decline in growth figures to determine the amount of lost sales. After subtracting the estimated costs that would have been incurred had the pharmaceuticals actually been manufactured and sold, the plaintiff claimed damages of almost $4,000,000 on all products including, approximately $2,800,000 for the products that hаd been the subject of Medique’s unfair practices.
Noting that Medique’s total sales were less than half of the claimed lost sales, the district court specifically emphasized that Otis Clapp had failed to prove a single lost sale. Turning to a detailed analysis of the plaintiff’s data, the district court pointed out that, in 1978, when the unfair trade practices “were pursued with full vigor,” the company’s overall growth rate was double the 1977 rate. Furthermore, in 1982, when the unfair practices had ceased, the growth rate was “a negative 15 percent, the only sales decline during the entire period.” After similarly analyzing the figures for the individual products, the district court concluded that, “the evidence
The factual determinations of district courts will not be set aside unless clearly erroneous.
The second contested element of damages was the award of attorney’s fees.
The district court found that, “the ‘targeting’ of plaintiff by defendant in its literature was in cavalier disregard of the objective truth. Plaintiff has for years been haunted by defendant’s singling out plaintiff as the whetstone upon which it has unfairly sharpened its competitive weapons.” We concur with the district court’s judgment that the defendant’s actions make this an exceptional case justifying an award of attorney’s fees. On the other hand, the district court found that the plaintiff had “overreacted to the impact of defendant’s conduct and that an action
The decision of the district court is AFFIRMED.
Notes
. Rose was also sued for breach of contract, trade disparagement, unfair competition, and interference with the plaintiff’s business relationships. The plaintiff later dropped its action against Rose.
. Claims against Rose, the former Otis Clapp employee, were added in 1979. As was explained in note 1, supra, the claims against Rose were dropped.
. As will be more fully explained below, the plaintiff attempted to prove what its grоwth should have been based upon its previous rate of growth.
. Schwartz examined the statements of the old Filmore Vitamin Company, the company that became I. Udell & Associates, Inc.
. The district court also granted injunctive relief which has not been appealed.
. "
“(c) Transfer of Interest. In case of any transfer of interest, the action may be continued by or against the original party, unlessthe court upon motion directs the person to whom the interest is transferred to be substituted in the action or joined with the original party. Service of the motion shall be made as provided in subdivision (a) of this rule.”
. "
“(b) Joinder of Remedies; Fraudulent Conveyances. Whenever a claim is one heretofore cognizable only after another claim has been prosecuted to a conclusion, the two claims may be joined in a single action; but the court shall grant relief in that action only in accordance with the relative substantive rights of the parties. In particular, a plaintiff may state a claim for money and a claim to have set aside a conveyance fraudulent as to him, without first having obtained a judgment establishing the claim for money.”
. Our analysis of the unrealized growth potential claim includes the claim for loss of goodwill since both were based on the same financial evidence.